A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin.
Adenocarcinoma
/ drug therapy
Administration, Intravenous
/ adverse effects
Antineoplastic Agents
/ adverse effects
Carcinoma, Neuroendocrine
/ drug therapy
Cisplatin
/ adverse effects
Esophageal Neoplasms
/ drug therapy
Esophagogastric Junction
/ pathology
Exophthalmos
/ chemically induced
Glucocorticoids
/ therapeutic use
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Oculomotor Muscles
/ diagnostic imaging
Optic Nerve
/ diagnostic imaging
Receptor, ErbB-2
/ metabolism
Adverse events
Cisplatin
Gastrointestinal cancer
Journal
Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
08
2018
accepted:
08
11
2018
pubmed:
26
2
2019
medline:
20
8
2019
entrez:
26
2
2019
Statut:
ppublish
Résumé
Mixed adenoneuroendocrine carcinomas (MANECs) are rare malignancies with both neuroendocrine and non-neuroendocrine components. To date, the prognosis of gastroenteropancreatic MANECs remains dismal, and treatment options are mainly based on guidelines for the treatment of pure neuroendocrine carcinomas or small cell lung cancer. Established first-line therapy in the metastatic situation is cisplatin and etoposide. Platinum derivatives are known to cause a variety of side effects also involving the visual system. Severe orbital and optic nerve toxicities have been described mainly after intracarotid infusion of cisplatin. Herein we report a rare case of a 60-year-old male patient suffering from MANEC of the gastroesophageal junction with HER2/neu overexpression who developed severe orbital and ocular neurotoxicity (grade 3 according to CTCAE v4.03) after intravenous cisplatin. We discuss diagnostic approaches and differential diagnoses in this clinical situation. Before starting treatment with intravenous and topical steroids, it is crucial to rule out meningeal and cerebral spread as well as paraneoplastic and endocrine syndromes.
Sections du résumé
BACKGROUND
BACKGROUND
Mixed adenoneuroendocrine carcinomas (MANECs) are rare malignancies with both neuroendocrine and non-neuroendocrine components. To date, the prognosis of gastroenteropancreatic MANECs remains dismal, and treatment options are mainly based on guidelines for the treatment of pure neuroendocrine carcinomas or small cell lung cancer. Established first-line therapy in the metastatic situation is cisplatin and etoposide. Platinum derivatives are known to cause a variety of side effects also involving the visual system. Severe orbital and optic nerve toxicities have been described mainly after intracarotid infusion of cisplatin.
CASE REPORT
METHODS
Herein we report a rare case of a 60-year-old male patient suffering from MANEC of the gastroesophageal junction with HER2/neu overexpression who developed severe orbital and ocular neurotoxicity (grade 3 according to CTCAE v4.03) after intravenous cisplatin.
CONCLUSION
CONCLUSIONS
We discuss diagnostic approaches and differential diagnoses in this clinical situation. Before starting treatment with intravenous and topical steroids, it is crucial to rule out meningeal and cerebral spread as well as paraneoplastic and endocrine syndromes.
Identifiants
pubmed: 30799422
pii: 000495218
doi: 10.1159/000495218
doi:
Substances chimiques
Antineoplastic Agents
0
Glucocorticoids
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Cisplatin
Q20Q21Q62J
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
123-127Informations de copyright
© 2019 S. Karger AG, Basel.